Aquestive Entered into a License, Development & Supply Agreement with Haisco to Develop and Commercialize Exservan (riluzole oral film) for ALS in China
Shots:
- Aquestive will receive $7M up front & is eligible to receive regulatory milestones along with royalties on net sales of Exservan in China & will earn manufacturing revenue as the exclusive supplier of Exservan
- Haisco will lead the regulatory & commercialization activities for Exservan in China. Aquestive will be responsible for an exclusive sole manufacturer & supplier of the product. The agreement will allow the patients to use Exservan & provides the treatment option to patients who have difficulties to swallow
- Aquestive gets an exclusive license under jointly developed intellectual property rights to develop & commercialize the products outside & inside of China for other indications
Ref: Globe Newwire | Image: Aquestive
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
